Compositions and methods for glioblastoma treatment

• US 9,364,532 B2
• Filed: 06/07/2012
• Issued: 06/14/2016
• Est. Priority Date: 06/08/2011
• Status: Active Grant

• Current Assignee: Children's Hospital of Eastern Ontario Research Institute
• Original Assignee: Children's Hospital of Eastern Ontario Research Institute
• Inventors: Stojdl, David F.
• Primary Examiner(s): Blumel, Benjamin P
• Assistant Examiner(s): SALVOZA, M FRANCO G
• Application Number:
  US14/123,057
• Publication Number:
  US 20140093527A1
• Time in Patent Office: 1,468 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/572 cytotoxic response
• CPC Class Codes: A61K 2039/585 wherein the target is cancer
• CPC Class Codes: A61K 35/766 Rhabdovirus, e.g. vesicular stomatitis virus
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/205 Rhabdoviridae, e.g. rabies virus
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2760/00032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2760/20021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2760/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2760/20023 Virus like particles [VLP]
• CPC Class Codes: C12N 2760/20032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2760/20043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynucleotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.

Claims

1. A method for inducing an immunogenic response in a patient, the method comprising administering to the patient an isolated viral particle having a genome comprising open reading frames that encode:

a protein comprising SEQ ID NO;

3;

a protein comprising SEQ ID NO;

4;

a protein comprising SEQ ID NO;

5;

a protein comprising SEQ ID NO;

6;

and a protein comprising SEQ ID NO;

7.

2. The method according to claim 1, wherein the isolated viral particle is administered directly to the central nervous system, outside the blood/brain barrier, inside the blood/brain barrier, or any combination thereof.

3. The method according to claim 2, wherein the isolated viral particle is administered to the patient intrathecally, intravenously or via intracranial injection.

4. The method according to claim 1, wherein a cell is infected with the isolated viral particle and the infected cell is administered to the patient.

5. The method according to claim 4, wherein the infected cell is administered directly to the central nervous system, outside the blood/brain barrier, inside the blood/brain barrier, or any combination thereof.

6. The method according to claim 5, wherein the infected cell is administered to the patient intrathecally, intravenously or via intracranial injection.

7. The method according to claim 1, wherein inducing an immunogenic response is against a malignant glioma in the brain of the patient, and wherein the method comprises administration of the isolated viral particle inside the blood/brain barrier.

8. The method according to claim 7, wherein the malignant glioma is a glioblastoma or medulloblastoma.